In TNT, six studies gathering four hundred and sixty eight patients found that pre-treatment markers associated with tumor response were as follows: low CEA levels, wild type TP53, SMAD4, KRAS and LRP1B, presence of the G-allele of LCS-6 and MRI features including short LN axis, smooth contour LN, homogeneous LN and Zhang et al. Rad score [35]. This evidence concerns the gene KRAS and neoplasm.